A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Feb 7

PMID 32024277

Citations 6

Authors

Akari Nakamura-Utsunomiya

Toshio Nakamae

Reiko Kagawa

Shuhei Karakawa

Sonoko Sakata

Fumiaki Sakura

Chihiro Tani

Yoshiko Matsubara

Takashi Ishino

Go Tajima

Satoshi Okada

Affiliations

Soon will be listed here.

Abstract

Background: Morquio A syndrome, mucopolysaccharidosis type IVA (MPS IVA), is a lysosomal storage disorder caused by the deficient activity of N-acetylgalactosamine-6-sulfatase (GalNac6S), due to alterations in the gene. This disorder results in marked abnormalities in bones and connective tissues, and affects multiple organs. Here, we describe the clinical course of a Japanese boy with MPS IVA who began enzyme replacement therapy (ERT) at the age of 24 months.

Patient: the patient presented for kyphosis treatment at 22 months of age. An X-ray examination revealed dysostosis multiplex. Uronic acids were elevated in the urine and the keratan sulfate (KS) fraction was predominant. The leukocyte GalNac6S enzyme activity was extremely low. The patient exhibited the c.463G > A (p.Gly155Arg) mutation in . Based on these findings, his disease was diagnosed as classical (severe) Morquio A syndrome. An elosulfase alfa infusion was initiated at the age of 24 months. The patient's body height improved from -2.5 standard deviation (SD) to -2 SD and his physical activity increased during the first 9 months on ERT. However, he gradually developed paralysis in the lower legs with declining growth velocity, which required cervical decompression surgery in the second year of the ERT. The mild mitral regurgitation, serous otitis media, and mild hearing loss did not progress during treatment.

Conclusion: early initiation of the elosulfase alfa to our patient showed good effects on the visceral system and muscle strength, while its effect on bones appeared limited. Careful observation is necessary to ensure timely surgical intervention for skeletal disorders associated with neurological symptoms. Centralized and multidisciplinary management is essential to improve the prognosis of pediatric patients with MPS IVA.

Citing Articles

Hearing loss in patients with Morquio A syndrome: A scoping review.

Diaz-Ordonez L, Duque-Cordoba P, Silva-Cuero K, Gutierrez-Medina J, Saldarriaga W, Murgasova L Medicine (Baltimore). 2025; 104(2):e41128.

PMID: 39792720 PMC: 11730861. DOI: 10.1097/MD.0000000000041128.

Adeno-Associated Virus Gene Transfer Ameliorates Progression of Skeletal Lesions in Mucopolysaccharidosis IVA Mice.

Herreno-Pachon A, Sawamoto K, Stapleton M, Khan S, Piechnik M, Alvarez J Hum Gene Ther. 2024; 35(23-24):955-968.

PMID: 39450470 PMC: 11659441. DOI: 10.1089/hum.2024.096.

Tracheal Resection for Critical Airway Obstruction in Morquio A Syndrome.

Frauenfelder C, Maughan E, Kenth J, Nandi R, Jones S, Walker R Case Rep Pediatr. 2023; 2023:7976780.

PMID: 37180285 PMC: 10171972. DOI: 10.1155/2023/7976780.

Burden of Surgical Treatment for the Management of Cervical Myelopathy in Mucopolysaccharidoses: A Systematic Review.

Costanzo R, Bonosi L, Porzio M, Paolini F, Brunasso L, Giovannini A Brain Sci. 2023; 13(1).

PMID: 36672030 PMC: 9856616. DOI: 10.3390/brainsci13010048.

The GALNS p.P77R variant is a probable Gujarati-Indian founder mutation causing Mucopolysaccharidosis IVA syndrome.

Sheth H, Naik P, Shah M, Bhavsar R, Nair A, Sheth F BMC Genomics. 2022; 23(1):458.

PMID: 35729508 PMC: 9210747. DOI: 10.1186/s12864-022-08693-4.

References

Matalon R, Arbogast B, Justice P, BRANDT I, DORFMAN A . Morquio's syndrome: deficiency of a chondroitin sulfate N-acetylhexosamine sulfate sulfatase. Biochem Biophys Res Commun. 1974; 61(2):759-65. DOI: 10.1016/0006-291x(74)91022-5. View

Doherty C, Stapleton M, Piechnik M, Mason R, Mackenzie W, Yamaguchi S . Effect of enzyme replacement therapy on the growth of patients with Morquio A. J Hum Genet. 2019; 64(7):625-635. DOI: 10.1038/s10038-019-0604-6. View

Kosuga M, Mashima R, Hirakiyama A, Fuji N, Kumagai T, Seo J . Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase. Mol Genet Metab. 2016; 118(3):190-197. DOI: 10.1016/j.ymgme.2016.05.003. View

Melbouci M, Mason R, Suzuki Y, Fukao T, Orii T, Tomatsu S . Growth impairment in mucopolysaccharidoses. Mol Genet Metab. 2018; 124(1):1-10. PMC: 5966322. DOI: 10.1016/j.ymgme.2018.03.004. View

Khan S, Almeciga-Diaz C, Sawamoto K, Mackenzie W, Theroux M, Pizarro C . Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab. 2016; 120(1-2):78-95. PMC: 5293636. DOI: 10.1016/j.ymgme.2016.11.007. View

Montano A, Tomatsu S, Brusius A, Smith M, Orii T . Growth charts for patients affected with Morquio A disease. Am J Med Genet A. 2008; 146A(10):1286-95. DOI: 10.1002/ajmg.a.32281. View

Gentili C, Cancedda R . Cartilage and bone extracellular matrix. Curr Pharm Des. 2009; 15(12):1334-48. DOI: 10.2174/138161209787846739. View

Alvarez J, Bravo S, Garcia-Vence M, De Castro M, Luzardo A, Colon C . Proteomic Analysis in Morquio A Cells Treated with Immobilized Enzymatic Replacement Therapy on Nanostructured Lipid Systems. Int J Mol Sci. 2019; 20(18). PMC: 6769449. DOI: 10.3390/ijms20184610. View

Tomatsu S, Montano A, Oikawa H, Smith M, Barrera L, Chinen Y . Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011; 12(6):931-45. DOI: 10.2174/138920111795542615. View

10.

Do Cao J, Wiedemann A, Quinaux T, Battaglia-Hsu S, Mainard L, Froissart R . 30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case. Mol Genet Metab Rep. 2016; 9:42-45. PMC: 5065040. DOI: 10.1016/j.ymgmr.2016.10.001. View

11.

Bank R, Groener J, van Gemund J, Maaswinkel P, Hoeben K, Schut H . Deficiency in N-acetylgalactosamine-6-sulfate sulfatase results in collagen perturbations in cartilage of Morquio syndrome A patients. Mol Genet Metab. 2009; 97(3):196-201. DOI: 10.1016/j.ymgme.2009.03.008. View

12.

Simonaro C, DAngelo M, He X, Eliyahu E, Shtraizent N, Haskins M . Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol. 2007; 172(1):112-22. PMC: 2189614. DOI: 10.2353/ajpath.2008.070564. View

13.

Jones S, Bialer M, Parini R, Martin K, Wang H, Yang K . Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y. Pediatr Res. 2015; 78(6):717-22. PMC: 4700045. DOI: 10.1038/pr.2015.169. View

14.

Isojima T, Kato N, Ito Y, Kanzaki S, Murata M . Growth standard charts for Japanese children with mean and standard deviation (SD) values based on the year 2000 national survey. Clin Pediatr Endocrinol. 2016; 25(2):71-6. PMC: 4860518. DOI: 10.1297/cpe.25.71. View

15.

Cattoni A, Motta S, Masera N, Gasperini S, Rovelli A, Parini R . The use of recombinant human growth hormone in patients with Mucopolysaccharidoses and growth hormone deficiency: a case series. Ital J Pediatr. 2019; 45(1):93. PMC: 6676577. DOI: 10.1186/s13052-019-0691-1. View

16.

Muhlebach M, Wooten W, Muenzer J . Respiratory manifestations in mucopolysaccharidoses. Paediatr Respir Rev. 2011; 12(2):133-8. DOI: 10.1016/j.prrv.2010.10.005. View

17.

Simonaro C, Ge Y, Eliyahu E, He X, Jepsen K, Schuchman E . Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A. 2009; 107(1):222-7. PMC: 2806747. DOI: 10.1073/pnas.0912937107. View

18.

Peracha H, Sawamoto K, Averill L, Kecskemethy H, Theroux M, Thacker M . Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA. Mol Genet Metab. 2018; 125(1-2):18-37. PMC: 6175643. DOI: 10.1016/j.ymgme.2018.05.004. View

19.

Hiramatsu M, Nakamura K . Elosulfase alfa enzyme replacement therapy attenuates disease progression in a non-ambulatory Japanese patient with Morquio A syndrome (case report). Mol Genet Metab Rep. 2017; 13:76-79. PMC: 5604956. DOI: 10.1016/j.ymgmr.2017.09.001. View

20.

Charrow J, Alden T, Breathnach C, Frawley G, Hendriksz C, Link B . Diagnostic evaluation, monitoring, and perioperative management of spinal cord compression in patients with Morquio syndrome. Mol Genet Metab. 2014; 114(1):11-8. DOI: 10.1016/j.ymgme.2014.10.010. View